MDT

96.23

+0.57%↑

VEEV

289.66

-0.12%↓

A

146.9

+1.03%↑

HQY

95.36

-0.24%↓

TLRY

1.41

-7.24%↓

MDT

96.23

+0.57%↑

VEEV

289.66

-0.12%↓

A

146.9

+1.03%↑

HQY

95.36

-0.24%↓

TLRY

1.41

-7.24%↓

MDT

96.23

+0.57%↑

VEEV

289.66

-0.12%↓

A

146.9

+1.03%↑

HQY

95.36

-0.24%↓

TLRY

1.41

-7.24%↓

MDT

96.23

+0.57%↑

VEEV

289.66

-0.12%↓

A

146.9

+1.03%↑

HQY

95.36

-0.24%↓

TLRY

1.41

-7.24%↓

MDT

96.23

+0.57%↑

VEEV

289.66

-0.12%↓

A

146.9

+1.03%↑

HQY

95.36

-0.24%↓

TLRY

1.41

-7.24%↓

Search

Immunocore Holdings PLC ADR

Ouvert

31.64 -4.76

Résumé

Variation du prix de l'action

24h

Actuel

Min

31.1

Max

33.61

Chiffres clés

By Trading Economics

Revenu

-15M

-10M

Ventes

4.1M

98M

Marge bénéficiaire

-10.514

Employés

493

EBITDA

-11M

-15M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+74.16% upside

Dividendes

By Dow Jones

Prochains Résultats

4 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

2M

1.6B

Ouverture précédente

36.4

Clôture précédente

31.64

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Immunocore Holdings PLC ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 oct. 2025, 23:55 UTC

Actions en Tendance

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

21 oct. 2025, 23:49 UTC

Résultats

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

21 oct. 2025, 21:40 UTC

Résultats

Waste Connections 3Q Revenue Rises

21 oct. 2025, 21:14 UTC

Résultats
Principaux Mouvements du Marché

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

21 oct. 2025, 21:05 UTC

Acquisitions, Fusions, Rachats

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

21 oct. 2025, 20:57 UTC

Acquisitions, Fusions, Rachats

DraftKings to Launch Prediction Markets Platform

21 oct. 2025, 20:38 UTC

Résultats

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

21 oct. 2025, 20:35 UTC

Résultats

Capital One 3Q Sales, Profit Jump

21 oct. 2025, 20:32 UTC

Résultats

Texas Instruments 3Q Revenue Up on Growth Across End Markets

21 oct. 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 oct. 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

21 oct. 2025, 23:39 UTC

Market Talk

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

21 oct. 2025, 23:36 UTC

Market Talk

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

21 oct. 2025, 22:55 UTC

Acquisitions, Fusions, Rachats

Scentre Says This Forms Part of Capital Management Strategy

21 oct. 2025, 22:55 UTC

Acquisitions, Fusions, Rachats

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

21 oct. 2025, 22:54 UTC

Acquisitions, Fusions, Rachats

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

21 oct. 2025, 21:09 UTC

Market Talk
Résultats

Netflix Creators Have Started Using AI in Production -- Market Talk

21 oct. 2025, 20:58 UTC

Market Talk
Résultats

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

21 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 oct. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

21 oct. 2025, 20:43 UTC

Résultats

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

21 oct. 2025, 20:41 UTC

Résultats

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

21 oct. 2025, 20:33 UTC

Acquisitions, Fusions, Rachats

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

21 oct. 2025, 20:33 UTC

Acquisitions, Fusions, Rachats

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

21 oct. 2025, 20:31 UTC

Acquisitions, Fusions, Rachats

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

21 oct. 2025, 20:29 UTC

Résultats

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Comparaison

Variation de prix

Immunocore Holdings PLC ADR prévision

Objectif de Prix

By TipRanks

74.16% hausse

Prévisions sur 12 Mois

Moyen 59.11 USD  74.16%

Haut 100 USD

Bas 34 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

7

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

27.895 / 30.16Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
help-icon Live chat